William J. Gradishar, MD

Articles

Dr. Gradishar on the Treatment Landscape in Metastatic HER2+ Breast Cancer

October 9th 2020

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

Dr. Gradishar on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Dr. Gradishar on Personalized Treatment in Breast Cancer

October 17th 2018

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

March 30th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of HER2-positive breast cancer.

Dr. Gradishar on Using Genetic Testing to Identify Actionable Results in Breast Cancer

March 9th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.

Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

October 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

October 13th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

August 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

December 17th 2014

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

Gradishar Provides Insight into New Breast Cancer Treatments

January 21st 2014

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

x